Spun out of GlaxoSmithKline Pharmaceuticals (GSK) in 2010, Transpharmation was created to be a CRO with a difference; cross-therapeutic area expertise in translational pharmacology from bench to bedside.
With headquarters based in central London, England and laboratories just north of the Captial, Transpharmation is rapidly growing and bucking the trend in the languishing CRO market since the financial crisis in 2007/2008.
Transpharmation is led by a team with years of proven hands-on drug discovery and business expertise. This has allowed us to build client and science-focused relationships, across our extensive network in the pharmaceutical and biotechnology sectors.
Our mission is simple; we wish to be known as the market leader in the provision of innovation and science-led translational biology. We believe, we have made significant steps to achieving this goal and invite you to explore our website to further understand how our strategy can enhance your Drug Discovery programmes.
We are constantly looking for novel preclinical/clinical assays, technologies and endpoints that increase your success. Wherever possible we strive to publish our research in peer reviewed journals.
A CRO should offer technologies you do not have in your own company. Investment in technology, bringing capabilities together, underpins our desire to innovate & produce multiple endpoints to a single study.